Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin αV and integrin β3 in human neuroendocrine tumors

Oncology Reports

Volumn 21, Issue 3, 2009, Pages 769-775

  Oxboel, Jytte ^a,b   Binderup, Tina ^a,b   Knigge, Ulrich ^a,b   Kjaer, Andreas ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Gene expression; Integrin V3; Neuroendocrine tumor; Tumor angiogenesis; VEGF

Indexed keywords

BETA3 INTEGRIN; CD34 ANTIGEN; CD51 ANTIGEN; MESSENGER RNA; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MALE; NEUROENDOCRINE TUMOR; NUCLEOTIDE SEQUENCE; PATIENT SELECTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; INTEGRIN ALPHAV; INTEGRIN BETA3; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 64849117301     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000283     Document Type: Article

References (40)

1. Takeda A, Stoeltzing O, Ahmad SA, et al: Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 9: 610-616, 2002.
2. Ruegg C, Dormond O and Mariotti A: Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochim Biophys Acta 1654: 51-67, 2004.
3. Ruegg C and Mutter N: Anti-angiogenic therapies in cancer: achievements and open questions. Bull Cancer 94: 753-762, 2007.
4. Diaz R, Pena C, Silva J, et al: p73 Isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. Int J Cancer 123: 1060-1067, 2008.
5. Kobayashi H, Sugihara K, Uetake H, et al: Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis. Ann Surg Oncol 15: 1232-1238, 2008.
6. Kuramochi H, Hayashi K, Uchida K, et al: Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 12: 29-33, 2006.
7. Jin H and Varner J: Integrins: roles in cancer development and as treatment targets. Br J Cancer 90: 561-565, 2004.
8. Varner JA and Cheresh DA: Integrins and cancer. Curr Opin Cell Biol 8: 724-730, 1996.
9. Guo W and Giancotti FG: Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5: 816-826, 2004.
10. Ruegg C, Meuwly JY, Driscoll R, et al: The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. Curr Mol Med 3: 673-691, 2003.
11. Cai W, Rao J, Gambhir SS, et al: How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther 5: 2624-2633, 2006.
12. Kolev Y, Uetake H, Iida S, et al: Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol 14: 2738-2747, 2007.
13. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
14. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) wit FU/LV alone in patients with metas-tatic colorectal cancer. J Clin Oncol 21: 60-65, 2003.
15. Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23: 3697-3705, 2005.
16. Dechantsreiter MA, Planker E, Matha B, et al: N-Methylated cyclic RGD peptides as highly active and selective alpha(V) beta(3) integrin antagonists. J Med Chem 42: 3033-3040, 1999.
17. Albert JM, Cao C, Geng L, et al: Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small cell lung cancer models. Int J Radiat Oncol Biol Phys 65: 1536-1543, 2006.
18. Burke PA, DeNardo SJ, Miers LA, et al: Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radio-immunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62: 4263-4272, 2002.
19. Friess H, Langrehr JM, Oettle H, et al: A randomized multicenter phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6: 285, 2006.
20. Loges S, Butzal M, Otten J, et al: Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Biochem Biophys Res Commun 357: 1016-1020, 2007.
21. Nabors LB, Mikkelsen T, Rosenfeld SS, et al: Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25: 1651-1657, 2007.
22. Yamada S, Bu XY, Khankaldyyan V, et al: Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 59: 1304-1312, 2006.
23. Oberg K, Astrup L, Eriksson B, et al: Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol 43: 626-636, 2004.
24. Oberg K, Astrup L, Eriksson B, et al: Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol 43: 617-625, 2004.
25. Oberg K: Management of neuroendocrine tumours. Ann Oncol 15 (Suppl. 4): iv293-iv298, 2004.
26. Binderup T, Knigge U, Mellon Mogensen A, Palnaes Hansen C, Kjaer A: Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology 87: 223-232, 2008.
27. Zhang J, Jia Z, Li Q, et al: Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109: 1478-1486, 2007.
28. Andersen CL, Jensen JL and Orntoft TF: Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64: 5245-5250, 2004.
29. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
30. Ellis LM: Angiogenesis and its role in colorectal tumor and metastasis formation. Semin Oncol 31: 3-9, 2004.
31. Stoeltzing O, Liu W, Reinmuth N, et al: Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann Surg Oncol 10: 722-733, 2003.
32. Mancuso A and Sternberg CN: Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice? Crit Rev Oncol Hematol 55: 67-81, 2005.
33. Vonlaufen A, Wiedle G, Borisch B, et al: Integrin alpha(v) beta(3) expression in colon carcinoma correlates with survival. Mod Pathol 14: 1126-1132, 2001.
34. Cai W and Chen X: Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 6: 407-428, 2006.
35. Haubner R, Weber WA, Beer AJ, et al: Non-invasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2: e70, 2005.
36. Kulke MH, Stuart K, Enzinger PC, et al: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24: 401-406, 2006.
37. Beer AJ, Haubner R, Sarbia M, et al: Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 12: 3942-3949, 2006.
38. Beer AJ, Haubner R, Wolf I, et al: PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 47: 763-769, 2006.
39. Liu S: Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm 3: 472-487, 2006.
40. Haubner R: alpha(v)beta (3)-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 33 (Suppl. 13): 54-63, 2006.